| |
Physician Home |
Clinical Data |
JNM PET Literature |
Introduction
Contents:
Introduction
This special supplement to The Journal of Nuclear Medicine
is a detailed tabulation of literature on FDG PET in oncology (1993 - June
2000), cardiology (1986 - June 2000), and neurology (1980 - June
2000). This document is a subset of the original document formally
submitted to the Health Care Financing Administration (HCFA) in
July 2000 to request expanded Medicare reimbursement for FDG PET. It
has been improved by eliminating any errors in tabulation and further
clarified as the result of comments from an independent review of the
original HCFA submission. This document also differs from the
original HCFA submission in that it does not include some background
sections and lacks references that were identified but not used
because of specific inclusion and exclusion criteria.
Because of the difficulty of searching all FDG PET literature,
this document inevitably does not include some research articles
and abstracts that may be useful. The authors have tried to
make the search as comprehensive as possible, but some literature
may have been overlooked. Details of the literature search strategy
are provided in Appendix A. Although a formal meta-analysis was
not performed, a simple weighted averaging of data using various
strategies is presented (Appendix B). This weighted averaging is
meant to give only a general indication of the overall accuracy
values and, therefore, should be interpreted with care. A data
pooling analysis is also included.
The document is organized to show, first, how the tabulated data
should be interpreted. This is followed by oncologic, cardiac, and
neurologic application sections that provide, for each disease
process, a disease background section, a case example illustrating
the clinical implementation of FDG PET, an explanation of why
FDG PET helped, a key management issues section (see also Maisey
et al. (285), and a summary of evidence for FDG PET with
management change data for the disease and references to the relevant
full literature search (in tabulated form) for the accuracy of
FDG PET in specific applications. The numbers of patient studies
utilized in calculating summary management changes are displayed
in
Tables
20
and
24 along with management figures and are embedded (without display)
within the individual spreadsheets as selected from the data lines
that report management change information. In addition, a summary of
results from the literature search on FDG PET in all cancers is
provided, as well as a summary of FDG PET literature searched for the
oncologic, cardiac, and neurologic applications. A full reference
list is also provided at the end. Appendix A gives details on the way
in which literature was searched and analyzed, and Appendix B reports
some alternate approaches to summarizing the data.
|
View this
table:
[Click here]
|
TABLE 20 FDG PET in Cancer: Summary of
Results of Literature Search
|
|
View this
table: [Click Here]
|
TABLE 24 Summary of Results of FDG PET Literature Search
|
The
average FDG PET sensitivity and specificity across all oncology
applications are estimated at 84% (based on 18,402 patient studies)
and 88% (based on 14,264 patient studies), respectively. The
average management change across all applications is estimated
to be 30% (based on 5,062 patients). Data was obtained
combining 419 total articles and abstracts on studies in which
FDG PET was used. Various methods of analysis were applied to
these data (Table
25), which revealed only a small amount of variation in the ratio
values. Specifically, the sensitivity of PET ranged from 84 - 87%, the
specificity ranged from 88% - 93%, and the accuracy ranged from
87 - 90%.
The goal of this document is to provide a summary of all FDG PET
literature for the specified periods, with tabulated values of
sensitivity, specificity, percentage in management changes, etc. This
document is not intended to be a formal meta-analysis or
cost-effectiveness analysis of the available literature. Instead, it
is meant to provide an overview of the available literature, so that
future detailed studies can use this document as a starting
point.
View this
table:
[Click here]
|
TABLE 25 Data Analysis Summary
|
At
the time of submission of this work, HCFA had just announced expanded
coverage for FDG PET to include imaging for various aspects of lung,
colorectal, esophageal, head and neck cancers, melanoma and
lymphoma. In addition, coverage for seizure work-ups and myocardial
viability was approved. We are confident that with continued
acquisition of data from well-designed clinical studies, true broad
coverage for FDG PET can soon be a reality. We hope that readers of
the journal will find this to be a valuable resource in better
understanding the existing diversity of literature available for FDG
PET.
Next:
Interpreting Spreadsheets In This Document
|